ALNUQTI

Serial Number 98064690
732

Registration Progress

Application Filed
Jun 29, 2023
Under Examination
Feb 13, 2024
Approved for Publication
Dec 19, 2023
Published for Opposition
Dec 19, 2023
Registered

Attorney Assistance

Statement of Use Due - Extension 3 Granted
Due: Feb 13, 2026 179 days

Trademark Image

ALNUQTI

Basic Information

Serial Number
98064690
Filing Date
June 29, 2023
Published for Opposition
December 19, 2023
Drawing Code
4

Status Summary

Current Status
Active
Status Code
732
Status Date
Jul 30, 2025
Application
Pending
Classes
005

Rights Holder

Bristol-Myers Squibb Company

03
Address
Route 206 & Province Line Road
Princeton, NJ 08543

Ownership History

Bristol-Myers Squibb Company

Original Applicant
03
Princeton, NJ

Bristol-Myers Squibb Company

Owner at Publication
03
Princeton, NJ

Legal Representation

Attorney
Marilyn F. Kelly

USPTO Deadlines

Next Deadline
179 days remaining
Statement of Use Due - Extension 3 Granted
Due Date
February 13, 2026
Extension Available
Until February 13, 2025

Application History

27 events
Date Code Type Description Documents
Jul 31, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jul 30, 2025 EX3G S SOU EXTENSION 3 GRANTED Loading...
Jul 30, 2025 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jul 30, 2025 EXT3 S SOU EXTENSION 3 FILED Loading...
Mar 4, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jan 27, 2025 EX2G S SOU EXTENSION 2 GRANTED Loading...
Jan 27, 2025 EXT2 S SOU EXTENSION 2 FILED Loading...
Jan 27, 2025 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jul 25, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jul 25, 2024 EXT1 S SOU EXTENSION 1 FILED Loading...
Jul 25, 2024 EX1G S SOU EXTENSION 1 GRANTED Loading...
Jul 25, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Feb 13, 2024 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Dec 19, 2023 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Dec 19, 2023 PUBO A PUBLISHED FOR OPPOSITION Loading...
Nov 29, 2023 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Nov 9, 2023 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Nov 8, 2023 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Nov 7, 2023 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Nov 7, 2023 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Aug 11, 2023 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Aug 11, 2023 GNRT F NON-FINAL ACTION E-MAILED Loading...
Aug 11, 2023 DOCK D ASSIGNED TO EXAMINER Loading...
Aug 11, 2023 CNRT R NON-FINAL ACTION WRITTEN Loading...
Aug 2, 2023 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Aug 1, 2023 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jul 3, 2023 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use

Classification

International Classes
005